Replies to post #14206 on Momenta Pharmaceuticals, Inc. (MNTA)

[DewDiligence]

I think we can assume that all logical flaws in the SG brief are discussed in the Amphastar reply.

The copious redactions in Amphstar’s brief make it hard to tell what the poster has in mind, specifically.